Literature DB >> 23106259

Lipaemic plasma induces haemolysis in resuspended red cell concentrate.

S Bashir1, M Wiltshire, R Cardigan, S Thomas.   

Abstract

INTRODUCTION: We investigated whether haemolysis in red cells suspended in plasma was affected by the lipid content and/or methylene blue (MB) treatment of fresh-frozen plasma (FFP). We also investigated whether haemolysis was affected by the conditions under which lipaemic plasma was stored.
METHODS: Study 1: Visibly lipaemic (n = 22) or nonlipaemic FFP (n = 24) units were thawed, pooled and split into identical pairs, one of which was MB treated. These units were used to resuspend red cell concentrates (RCC) and tested for haemolysis immediately and after 24 and 48 h of storage at 2-6°C. Study 2: Fresh plasma was aliquoted into 15-ml tubes and stored in one of four ways as follows: room temperature; 2-6°C; frozen and thawed; or twice frozen and thawed. A sample of RCC was resuspended in each of these plasmas and haemolysis measured after 2 h. Study 3: Plasma was divided into 15-ml tubes and stored as in study 2 followed by storage left standing upright in a refrigerator (2-6°C) for 24 h (with the exception of the room temperature sample). Plasma was separated into top, middle and bottom fractions and used to resuspend RCC that were assessed for haemolysis after 2 h.
RESULTS: The levels of haemolysis in RCC were immediately greater when suspended in lipaemic plasma (0·70 ± 0·53% v 0·05 ± 0·06% for nonlipaemic plasma), which increased further on subsequent storage for 48 h (1·22 ± 0·40% v 0·15 ± 0·14% for nonlipaemic plasma). This was irrespective of whether plasma was MB treated. Lipaemic plasma stored frozen and then thawed resulted in the greatest haemolysis. In lipaemic plasma stored at 2-6°C, the chylomicron-rich top fraction caused the highest level of haemolysis.
CONCLUSION: Haemolysis in red cells is increased in those suspended in lipaemic plasma and is dependent upon the storage conditions of that plasma prior to suspension. These data are relevant to the choice of plasma used to suspend red cells for neonatal exchange transfusion.
© 2012 The Author(s). Vox Sanguinis © 2012 International Society of Blood Transfusion.

Entities:  

Keywords:  haemolysis; lipaemic plasma; lipids; red cells; temperature

Mesh:

Substances:

Year:  2012        PMID: 23106259     DOI: 10.1111/j.1423-0410.2012.01660.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

Review 1.  Red blood cell components: time to revisit the sources of variability.

Authors:  Rosemary L Sparrow
Journal:  Blood Transfus       Date:  2017-03       Impact factor: 3.443

2.  Lifestyle behaviours are not associated with haemolysis: results from Donor InSight.

Authors:  Rosa de Groot; Jeroen Lakerveld; Johannes Brug; Johan W Lagerberg; Dirk de Korte; Trynke Hoekstra; Wim L A M de Kort; Katja van den Hurk
Journal:  Blood Transfus       Date:  2019-10-21       Impact factor: 3.443

3.  Determining the Volume of Additive Solution and Residual Plasma in Whole Blood Filtered and Buffy Coat Processed Red Cell Concentrates.

Authors:  Andrew Jordan; Jason P Acker
Journal:  Transfus Med Hemother       Date:  2015-11-05       Impact factor: 3.747

4.  Blood donor obesity is associated with changes in red blood cell metabolism and susceptibility to hemolysis in cold storage and in response to osmotic and oxidative stress.

Authors:  Kelsey Hazegh; Fang Fang; Marjorie D Bravo; Johnson Q Tran; Marcus O Muench; Rachael P Jackman; Nareg Roubinian; Lorenzo Bertolone; Angelo DʼAlessandro; Larry Dumont; Grier P Page; Tamir Kanias
Journal:  Transfusion       Date:  2020-11-04       Impact factor: 3.157

5.  Turbid plasma donations: Need for quantification.

Authors:  Naveen Agnihotri; Lokesh Kumar
Journal:  Asian J Transfus Sci       Date:  2014-07

6.  Frequency and causes of lipemia interference of clinical chemistry laboratory tests.

Authors:  Sandhya Mainali; Scott R Davis; Matthew D Krasowski
Journal:  Pract Lab Med       Date:  2017-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.